5 companies from Northern Ireland are participating in BIO Digital 2020.
Northern Ireland has a thriving life and health sciences sector offering expertise across a range of specialisms, including precision medicine, clinical trials and digital health. Northern Ireland also has clinical specialisms within the areas of oncology, cardiology, ophthalmology, respiratory and diabetes.
The sector includes global companies such as Almac, Randox, Norbrook, Bemis Healthcare, Actavis and Terumo. These businesses, which are a mix of international investors and indigenous companies continue to grow and prosper in the region – testament to Northern Ireland’s compelling proposition. Companies operating in the region benefit from access to an exceptionally skilled workforce, competitive operating costs, a pro-business environment, a sophisticated infrastructure and an existing cluster of synergistic businesses.
The region is home to internationally recognised universities, Queen’s University Belfast and Ulster University. Queen’s is a member of the Russell Group of the UK’s leading research intensive universities and Ulster University is one of the top 5 universities in the UK for world-leading research in biomedical sciences.
Northern Ireland’s Life & Health Sciences sector is renowned for housing some of the world’s most innovative companies in leading diagnostics. Following the World Health Organisation’s recommendation for the urgent need for testing, Northern Ireland companies including Randox, BioPanda Reagents and Fortress Diagnostics are rising to the challenge to develop fast tracking testing methods for the detection of COVID-19.
Invest Northern Ireland (Invest NI) is the economic development agency for this part of the UK. It promotes inward investment and trade with Northern Ireland from an extensive network of overseas offices, including its Americas HQ located in Boston.
Almac Group Limited
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. It is proud to be supporting 34 separate crucial research projects to help find a treatment for COVID-19.
Exploristics is a data analytics and enabling technology company that transforms clinical development for life science organisations with unique proprietary software and wraparound biostatistics services for planning, designing and analysing clinical studies. Exploristics has developed the Kerus platform, a cloud-based statistical modelling software dashboard allowing clinical trials planners to simulate trials and interrogate historical data to drive better trial design, reduce cost and accelerate trial reporting. The latest version of its unique Kerus platform - KerusCloud2 was launched in April 2020.
Fusion Antibodies increase the pace to the clinic for biotechnology and pharmaceutical organisations through services in antibody discovery, engineering and supply. Fusion enables clients to develop the best possible antibodies against their target getting them closer to their end-goal - the provision of treatments that improve the lives of patients throughout the world.
pHion Therapeutics is a therapeutic vaccine development company for the treatment of viral infections.
pHion’s peptide drug delivery system termed RALA, when combined with mRNA, generates a potent therapeutic CD8+ response, without provoking an innate immune response.
pHion’s RALA technology is also a safe, efficient and cost-effective solution for AAV production.
ProAxsisProAxsis specialises in the development of assays for the measurement of active protease biomarkers of disease. Three activity-based immunoassays are commercially available, targeting the respiratory biomarkers (Neutrophil Elastase (NE), Proteinase 3 and Plasmin), together with a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.